- $692.21m
- $460.10m
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Immix Biopharma, Inc. expected to post a loss of 18 cents a share - Earnings Preview
Brief: Immix Biopharma Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2
U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy
Brief: Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing
Brief: Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Brief: Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share
Brief: Immix Biopharma Says That 50% Enrollment Has Already Been Surpassed In NEXICART-2
Brief: Immix Biopharma Announces Strategic Investment By Houston Based Goose Capital, Led By Founding Member Dr. Nancy T. Chang
Immix Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Immix Biopharma Plans To Partner-Out Other Serious Disease Programs
Brief: Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview